Opioid REMS-Compliant Accredited CE Activities — 2020 Update

ACCME Highlights (09/21/20)

A new report from the Accreditation Council for Continuing Medical Education (ACCME) updates the scope of continuing education (CE) activities complying with the Food and Drug Administration's (FDA) Risk Evaluation and Mitigation Strategies (REMS) on opioid analgesics. The 2020 update concerns the Opioid Analgesic REMS (OA REMS) program, a 2018 expansion of the Extended-Release and Long-Acting Opioid Analgesics REMS. The report indicates that 24 accredited providers reported 213 OA REMS-compliant CE activities from March 1, 2020, through Aug. 15, 2020. Of those, 166 activities had been held or issued, with 44 more planned for the future. Most of those activities were offered as live courses, and accredited providers reported 111,358 learners for activities that had been held or released. Of these participants, 57% said they were registered to prescribe Schedule 2 or 3 drugs. Roughly 82% reported having an individual license and 18% said they had an institutional license. Physicians and advanced practice nurses formed the largest concentrations of learners who completed the CE activities.

Read More

Recent Stories
Alliance Podcast Episode 18: Spotlight on Leadership

Comparison of In-Person Versus Tele-Ultrasound Point-of-Care Ultrasound Training During the COVID-19 Pandemic

Rockpointe Presents Online CME Course on Treating High-Risk Patients With COVID-19